280 related articles for article (PubMed ID: 21934214)
1. Increased expression of COX-2 in recurrent basal cell carcinoma of the skin: a pilot study.
Karahan N; Baspinar S; Bozkurt KK; Caloglu E; Ciris IM; Kapucuoglu N
Indian J Pathol Microbiol; 2011; 54(3):526-31. PubMed ID: 21934214
[TBL] [Abstract][Full Text] [Related]
2. Increased immunoreactivity of membrane type-1 matrix metalloproteinase (MT1-MMP) and β-catenin in high-risk basal cell carcinoma.
Oh ST; Kim HS; Yoo NJ; Lee WS; Cho BK; Reichrath J
Br J Dermatol; 2011 Dec; 165(6):1197-204. PubMed ID: 21729023
[TBL] [Abstract][Full Text] [Related]
3. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2.
Zagrodnik B; Kempf W; Seifert B; Müller B; Burg G; Urosevic M; Dummer R
Cancer; 2003 Dec; 98(12):2708-14. PubMed ID: 14669293
[TBL] [Abstract][Full Text] [Related]
4. Role of cyclooxygenase-2, ezrin and matrix metalloproteinase-9 as predictive markers for recurrence of basal cell carcinoma.
El-Khalawany MA; Abou-Bakr AA
J Cancer Res Ther; 2013; 9(4):613-7. PubMed ID: 24518705
[TBL] [Abstract][Full Text] [Related]
5. Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas.
Betti R; Menni S; Radaelli G; Bombonato C; Crosti C
J Dermatol; 2010 Jul; 37(7):611-6. PubMed ID: 20629826
[TBL] [Abstract][Full Text] [Related]
6. Pattern of mRNA expression of beta-defensins in basal cell carcinoma.
Gambichler T; Skrygan M; Huyn J; Bechara FG; Sand M; Altmeyer P; Kreuter A
BMC Cancer; 2006 Jun; 6():163. PubMed ID: 16796735
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression.
O'Grady A; Dunne C; O'Kelly P; Murphy GM; Leader M; Kay E
Histopathology; 2007 Dec; 51(6):793-804. PubMed ID: 18042068
[TBL] [Abstract][Full Text] [Related]
8. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.
Byun JH; Lee MA; Roh SY; Shim BY; Hong SH; Ko YH; Ko SJ; Woo IS; Kang JH; Hong YS; Lee KS; Lee AW; Park GS; Lee KY
Jpn J Clin Oncol; 2006 May; 36(5):263-8. PubMed ID: 16735371
[TBL] [Abstract][Full Text] [Related]
9. Comparative morphometric analysis of primary versus recurrent basal cell carcinoma and of histological subtypes. Significance of morphometry of the nuclei.
Bierhoff E; Appel K; Appel T; Buettner R; Wardelmann E
Anticancer Res; 2003; 23(3B):2697-700. PubMed ID: 12894560
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of computer-assisted morphological and morphometrical analysis for detecting the recurrence tendency of basal cell carcinoma.
Cheretis C; Angelidou E; Dietrich F; Politi E; Kiaris H; Koutselini H
Med Sci Monit; 2008 May; 14(5):MT13-19. PubMed ID: 18443558
[TBL] [Abstract][Full Text] [Related]
11. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma. A possible indicator of differing causes.
McCormack CJ; Kelly JW; Dorevitch AP
Arch Dermatol; 1997 May; 133(5):593-6. PubMed ID: 9158412
[TBL] [Abstract][Full Text] [Related]
12. Duplicitous growth of infiltrative basal cell carcinoma: Analysis of clinically undetected tumor extent in a paired case-control study.
Hendrix JD; Parlette HL
Dermatol Surg; 1996 Jun; 22(6):535-9. PubMed ID: 8646468
[TBL] [Abstract][Full Text] [Related]
13. Microarray profiles of human basal cell carcinoma: insights into tumor growth and behavior.
Howell BG; Solish N; Lu C; Watanabe H; Mamelak AJ; Freed I; Wang B; Sauder DN
J Dermatol Sci; 2005 Jul; 39(1):39-51. PubMed ID: 15978418
[TBL] [Abstract][Full Text] [Related]
14. Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1 alpha-directed invasion of human basal cell carcinoma cells.
Chu CY; Cha ST; Chang CC; Hsiao CH; Tan CT; Lu YC; Jee SH; Kuo ML
Oncogene; 2007 Apr; 26(17):2491-501. PubMed ID: 17099730
[TBL] [Abstract][Full Text] [Related]
15. Expression of metalloproteinases (MMP-2 and MMP-9) in basal-cell carcinoma.
Goździalska A; Wojas-Pelc A; Drąg J; Brzewski P; Jaśkiewicz J; Pastuszczak M
Mol Biol Rep; 2016 Oct; 43(10):1027-33. PubMed ID: 27406386
[TBL] [Abstract][Full Text] [Related]
16. High numbers of human skin cancers express MMP2 and several integrin genes.
Orimoto AM; Neto CF; Pimentel ER; Sanches JA; Sotto MN; Akaishi E; Ruiz IR
J Cutan Pathol; 2008 Mar; 35(3):285-91. PubMed ID: 18251742
[TBL] [Abstract][Full Text] [Related]
17. Recurrent morphean basal cell carcinoma of the skin. A clinico-histopathological study of 97 cases.
Anthouli-Anagnostopoulou F; Hatziolou E
Adv Clin Path; 2002 Jan; 6(1):17-24. PubMed ID: 17582944
[TBL] [Abstract][Full Text] [Related]
18. Expression of basement membrane antigens and matrix metalloproteinases 2 and 9 in cutaneous basal and squamous cell carcinomas.
Dumas V; Kanitakis J; Charvat S; Euvrard S; Faure M; Claudy A
Anticancer Res; 1999; 19(4B):2929-38. PubMed ID: 10652575
[TBL] [Abstract][Full Text] [Related]
19. Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma.
Freier K; Flechtenmacher C; Devens F; Hartschuh W; Hofele C; Lichter P; Joos S
Oncol Rep; 2006 May; 15(5):1141-5. PubMed ID: 16596176
[TBL] [Abstract][Full Text] [Related]
20. Histological evolution of recurrent basal cell carcinoma and therapeutic implications for incompletely excised lesions.
Boulinguez S; Grison-Tabone C; Lamant L; Valmary S; Viraben R; Bonnetblanc JM; Bédane C
Br J Dermatol; 2004 Sep; 151(3):623-6. PubMed ID: 15377349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
